A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer
Gayle Jameson(HonorHealth), Nicholas J. Robert(Tufts Medical Center), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Kimberley A. Reeder(George Mason University), Julia Wulfkuhle(University of California, San Francisco), Stephen P. Anthony, Monica Fulk, Jasgit C. Sachdev(HonorHealth), Rosa I. Gallagher(George Mason University), Nina Cantafio(Translational Genomics Research Institute), Mariaelena Pierobon(George Mason University), Daniel D. Von Hoff(Translational Genomics Research Institute), William Mikrut(Vantage View (United States)), Lance A. Liotta(George Mason University), David Loesch(Caris Life Sciences (United States)), Manpreet Chadha, Bryant Dunetz(Side-Out Foundation)
Cited by 82
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k